Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3. No substantive content changes are visible.
    Difference
    0.1%
    Check dated 2026-03-06T17:49:35.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2. No changes to the study details, eligibility criteria, or outcomes were observed.
    Difference
    0.1%
    Check dated 2026-02-13T12:30:27.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The page shows Revision: v3.4.1 in place of Revision: v3.4.0. This appears to be a backend/template update with no changes to the study details.
    Difference
    0.1%
    Check dated 2026-02-05T18:56:58.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.4 in place of Revision: v3.3.3, indicating a metadata update with no changes to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T03:23:53.000Z thumbnail image
  7. Check
    83 days ago
    Change Detected
    Summary
    A new Locations section is added listing California, Maryland, and Minnesota sites. The HHS Vulnerability Disclosure link and the previously separate state location entries have been removed.
    Difference
    0.4%
    Check dated 2025-12-24T14:56:12.000Z thumbnail image
  8. Check
    111 days ago
    Change Detected
    Summary
    - Revision: v3.3.2 was added, replacing the previous Revision: v3.2.0.
    Difference
    0.1%
    Check dated 2025-11-25T21:09:53.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.